Rallybio (RLYB) Projected to Post Earnings on Thursday

Rallybio (NASDAQ:RLYB) is projected to announce its Q4 2025 results before the market opens on Thursday, March 12th. Analysts expect the company to announce earnings of ($1.04) per share for the quarter. Investors may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Tuesday, March 10, 2026 at 12:30 PM ET.

Rallybio Stock Performance

Rallybio stock opened at $10.51 on Thursday. The company’s 50 day simple moving average is $5.65 and its 200-day simple moving average is $5.20. Rallybio has a 1 year low of $1.76 and a 1 year high of $11.49. The company has a market capitalization of $55.49 million, a price-to-earnings ratio of -4.11 and a beta of -1.13.

Institutional Trading of Rallybio

Several hedge funds have recently modified their holdings of RLYB. XTX Topco Ltd raised its position in shares of Rallybio by 64.6% during the 4th quarter. XTX Topco Ltd now owns 97,313 shares of the company’s stock worth $67,000 after acquiring an additional 38,205 shares in the last quarter. Susquehanna International Group LLP boosted its holdings in Rallybio by 485.9% in the third quarter. Susquehanna International Group LLP now owns 136,294 shares of the company’s stock valued at $68,000 after purchasing an additional 113,031 shares in the last quarter. Geode Capital Management LLC increased its stake in Rallybio by 1.2% in the fourth quarter. Geode Capital Management LLC now owns 248,005 shares of the company’s stock valued at $170,000 after purchasing an additional 2,996 shares during the last quarter. Citadel Advisors LLC increased its stake in Rallybio by 576.1% in the third quarter. Citadel Advisors LLC now owns 438,705 shares of the company’s stock valued at $219,000 after purchasing an additional 373,821 shares during the last quarter. Finally, Renaissance Technologies LLC raised its holdings in Rallybio by 16.9% during the fourth quarter. Renaissance Technologies LLC now owns 835,692 shares of the company’s stock worth $573,000 after purchasing an additional 120,892 shares in the last quarter. 90.34% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Rallybio in a research report on Monday, December 29th. Four research analysts have rated the stock with a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Rallybio has a consensus rating of “Reduce” and a consensus price target of $40.00.

About Rallybio

Rallybio Therapeutics, Inc (NASDAQ: RLYB) is a clinical‐stage biotechnology company focused on developing and commercializing therapies for people living with rare genetic diseases. The company’s scientific approach leverages diverse modalities—including monoclonal antibodies, small molecules and enzyme replacement—to address high‐unmet‐need conditions in areas such as immunodeficiency, metabolic disorders and dermatologic diseases. Rallybio’s pipeline is designed to advance through registrational clinical trials with the goal of delivering first‐in‐class or best‐in‐class therapies to patients who currently have limited or no approved treatment options.

Among Rallybio’s lead programs is RBX‐100, an investigational therapy for congenital athymia, a rare pediatric immunodeficiency.